GeneNews is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases.
Latest News: Colon Cancer On Rise In Young Adults
ColonSentry® Can Asses Your Risk and Provide Actionable Clinical Information for Doctors and Patients
ColonSentry® is a blood-based test that can assess a patient's current risk of having colorectal cancer. The test is not considered a replacement for colonoscopy, but rather a more convenient step in determining early warning signs of colon cancer. ColonSentry does not require patients to provide a stool sample, nor does it require any dietary restrictions like fasting or refraining from certain foods or medications prior to taking the test. The ColonSentry test is easy to perform and blood can be drawn at the same time as other tests.
Our ColonSentry Test Is Now Available throughout U.S.
In The News
GeneNews' IDL off to flying start
BioTuesdays - GeneNews’ (TSX:GEN) recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL), took a huge step forward in the first quarter in its goal of becoming a leader in molecular diagnostics and personalized medicine.“With a successful limited scale launch of IDL in the fourth quarter of 2013, full scale-up activities began in the first quarter of this year, with a ramp up in lab capacity, a quadrupling of the size of the sales force, incrementally higher sales of our flagship ColonSentry test, and a rollout of new tests,” GeneNews’ executive chairman, James Howard-Tripp, says in an interview with BioTuesdays.com.
A total of 14,680 diagnostic tests were processed by IDL in the latest quarter, up 346% sequentially from 3,288 tests in the 2013 fourth quarter. Of these, 12,110 were ColonSentry. In April, the lab processed 13,600 tests. Read the full article.